linjc16/ctgov huggingface dataset:
The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University

Study Overview
=================
Brief Summary
-----------------
In this study, 100 female students aged 18 to 30 years old in Xiamen University will be enrolled. On the first visit, blood, saliva and urine samples of all participants will be collected. Then saliva and urine samples will be collected at two-week interval until 6 months. Serum samples will be tested the PP150-IgG titer. Saliva and urine samples will be used to test CMV DNA by PCR. The primary purpose of this study is to identify the relationship between baseline PP150-IgG titer and CMV infection.

Official Title
-----------------
The Epidemiologic Study of Human Cytomegalovirus （CMV）in Female Students of Xiamen University

Conditions
-----------------
Cytomegalovirus Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-30 years old female students of Xiamen University Exclusion Criteria: students who have the serious diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of active CMV infection in different PP150-IgG titer |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cytomegalovirus
Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane

Study Overview
=================
Brief Summary
-----------------
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.

Detailed Description
-----------------
The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in patients with severe acute kidney injury or sepsis, compared with standard membranes. Based on this benefit, the use of oXiris may confer better outcomes than other membranes. The patient outcomes include cardiovascular, respiratory, renal, and overall survivals, but this information of oXiris are insufficient. Although cytokine and endotoxin removal rates are great in oXiris, the beneficial effects on the hard outcomes are needed to use oXiris in real clinical practice. The inflammatory and cardiovascular systems have intensive crosstalk, and thus if there are remission in inflammatory process, the patients can have hemodynamic stability. Regarding this, the investigators would like to compare the hemodynamic stability between oXiris and other standard membrane such as polysulfone, using our new real-time monitoring registry.

Official Title
-----------------
Real-time Monitoring of Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy: Propensity Score-matched Comparison Between oXiris and Polysulfone Membranes

Conditions
-----------------
Acute Kidney Injury Due to Sepsis

Intervention / Treatment
-----------------
* Device: oXiris membrane
* Device: Polysulfone membrane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years Sepsis related acute kidney injury requiring continuous renal replacement therapy Exclusion Criteria: • No monitoring of blood pressure and ECG

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Septic AKI<br>Patients with septic acute kidney injury requiring continuous renal replacement therapy | Device: oXiris membrane<br>* Perform continuous renal replacement therapy with oXiris membrane<br>Device: Polysulfone membrane<br>* Perform continuous renal replacement therapy with polysulfone membrane<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of all-cause mortality | Risk of all-cause mortality | 28 days | 
| Occurrence rates of ventricular tachycardia, intradialytic hypotension | Risk of ventricular tachycardia, intradialytic hypotension | 28 days |
Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

Study Overview
=================
Brief Summary
-----------------
NRG1 gene fusions are extremely rare across solid tumours (estimate 0.3-0.5%). However, it is felt to be an actionable and potentially major growth pathway for those tumours that harbour this gene rearrangement. Tumours that harbour NRG1 fusions are driven by HER3 overactivation. Seribantumab is a mono-clonal antibody against HER3, it binds HER3 and inhibits NRG1-dependent activation and HER2 dimerization.

Official Title
-----------------
Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

Conditions
-----------------
Metastatic Pancreatic Cancer

Intervention / Treatment
-----------------
* Drug: Seribantumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Serious, life-threatening condition Not eligible for, or exhausted all other treatment options or causing significant toxicity No other way to access treatment Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Seribantumab<br>For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician. | Drug: Seribantumab<br>* For the induction phase: Seribantumab 3,000 mg IV weekly for 12 weeks then Maintenance Phase: Seribantumab 3,000 mg IV infusion once every 2 weeks, initiating approximately 14 days after completion of induction phase. Dose or schedule may be adjusted at the discretion of the treating physician.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival |  | 1 year |
Safety Study to Evaluate Intracranial Pressure During High Frequency Chest Wall Oscillation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate changes in intracranial pressure (ICP) during or immediately following high frequency chest wall oscillation (HFCWO) treatment with the Vest™ in neurosurgical subjects.

Detailed Description
-----------------
This study is a single site safety study to evaluate changes in intracranial pressure during or immediately following HFCWO treatment with the Vest™ in neurosurgical subjects with intracranial pressure monitors having normal opening pressures and ICP less than or equal to 20 mmHg. The secondary objective of this study is to evaluate changes in arterial blood gases that may result with Vest™ therapy in ventilated patients.

Official Title
-----------------
A Safety Study to Evaluate Intracranial Pressure With the Utilization of High Frequency Chest Wall Oscillation (HFCWO) Using the Vest™ on Mechanically Ventilated Neurosurgical Patients

Conditions
-----------------
Intracranial Pressure

Intervention / Treatment
-----------------
* Device: High Frequency Chest Wall Oscillation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICP monitor with normal opening pressure (greater than or equal to 20 mmHg) On ventilator Arterial line in place Age equal to or greater than 18 Admitted to neurotrauma intensive care unit (ICU) Exclusion Criteria: Inability to obtain informed consent Unstable spinal cord injury ICP > 20 mmHg sustained for > 5 minutes Hemodynamic instability within the prior 12 hours Active hemoptysis Hemothorax New onset, unstable arrhythmia Enrollment in another interventional study Aneurysm that has not been clipped or coiled Coagulopathic head injury subjects

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: High Frequency Chest Wall Oscillation|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intracranial pressure |  |  | 
| SpO2 |  |  | 
| Heart rate |  |  | 
| Mean arterial pressure (MAP) |  |  | 
| Arterial blood gases (ABGs) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial pressure, High Frequency Chest Wall Oscillation, Neurosurgery
Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
We propose to study the intestinal secretion of ASCA by evaluating them in biopsy culture supernatants from a cohort of patients suffering from CD (n=80) and a cohort of control patients (UC (n=40) and patients without IBD (n=40 )).

Detailed Description
-----------------
Its diagnosis is based upon clinical, endoscopic and histological parameters but recent studies have shown that seric evaluation of immunological markers (anti-Saccharomyces cerevisiae antibodies (ASCA), anti-neutrophil cytoplasmic auti-antibodies (ANCA)) could be useful. Crohn's disease (CD) is an inflammatory bowel disease (IBD) of the young people. Antibodies anti-chitobisoside carbohydrate (ACCA), anti-laminaribioside carbohydrate (ALCA) and anti-mannobioside carbohydrate (AMCA) have been described as new serological markers of CD.

Official Title
-----------------
Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Other: Blood sampling and biopsy
* Other: Biopsy and blood sampling
* Other: Biopsy and blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients reached by disease of crohn patients reached by hemorrhagic first side-colitis Exclusion Criteria: Forms ileales or ano-périneales pure of disease of crohn indefinite colitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Patients with crohn disease | Other: Blood sampling and biopsy<br>* Biopsy and blood : Research for various antibodies<br>|
| Other: 2<br>Patients reached by hemorrhagic first side-colitis | Other: Biopsy and blood sampling<br>* Biopsy and blood : research for various antibodies<br>|
| Other: 3<br>Patients controls | Other: Biopsy and blood sampling<br>* Blood and biopsy : research for various antibodies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare the performances of the dosage of the ASCA in floating it of culture of intestinal biopsies in that of their dosage in the serum |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine if the patients reached by disease of crohn not presenting ASCA in their serum represent one under group of disease of crohn |  | 24 months |
GLP-2 (Glucagonlike Peptide-2) and Blood Flow

Study Overview
=================
Brief Summary
-----------------
It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put. GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure. The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

Detailed Description
-----------------
se the above

Official Title
-----------------
The Role of GLP-2 in Univercal Changes in Blood Flow in Humans

Conditions
-----------------
Regional Blood Flow

Intervention / Treatment
-----------------
* Other: Glucagonlike peptide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 20-60 Healthy No medication Not pregnant Exclusion Criteria: All of the persons not meeting the abowe mentioned criteria

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>450 nmol GLP-2 SC | Other: Glucagonlike peptide<br>* 450 nmol native form, synthetic<br>|
| Placebo Comparator: 2<br>1 ml isotonic saline SC | Other: Glucagonlike peptide<br>* 450 nmol native form, synthetic<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| effect of glp-2 |  | during study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| potential new ideas for further studies |  | months to years |
A Comparative Study of the Effectiveness of Treatment of Contractures With Mechanically Applied Stretch and Heat.

Study Overview
=================
Brief Summary
-----------------
This study is looking at new ways to stretch knee contractures in children with cerebral palsy using a specially designed splint.

Detailed Description
-----------------
When using active orthoses to treat contractures, is the effectiveness of treatment improved by heating the contracted tissue prior to treatment?

Official Title
-----------------
A Comparative Study of the Effectiveness of Treatment of Contractures With Mechanically Applied Stretch and Heat.

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Device: With heat
* Device: No heat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with cerebral palsy - Exclusion Criteria: absent thermal sensation -

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: With heat<br>heat applied to contracted tissues prior to using the active stretching orthosis. | Device: With heat<br>* heat pad followed by dynamic splinting<br>* Other names: heat pad followed by dynamic splinting;|
| Placebo Comparator: Without heat<br>No heat applied to the contracted tissues prior to using the stretching orthosis | Device: No heat<br>* No heat added to tissue prior to dynamic splinting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Range of motion | 15 degree change in RoM | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cerebral palsy, dynamic splinting, contractures, heat therapy
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma

Study Overview
=================
Brief Summary
-----------------
This is a prospective, observational diagnostic study aiming to assess multiparametric MRI-based clinico-radiomics for identifying lymph node metastasis status in hilar cholangiocarcinoma.

Detailed Description
-----------------
A preoperative tool capable of predicting lymph node metastasis status in hilar cholangiocarcinoma is lacking and urgently needed for clinical practice. This study proposes to establish and evaluate a machine-learning algorithms of multiparametric MRI-based clinico-radiomics for identifying lymph node metastasis status in hilar cholangiocarcinoma. This study will investigate the relationship between radiomic depth information and tumor biological characteristics. The study includes the construction of capable MRI-based clinico-radiomics prediction model and the validation of the prediction model.

Official Title
-----------------
Evaluation of a MRI-based Clinico-radiomics Model in Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma Patients: a Prospective Diagnostic Study

Conditions
-----------------
Hilar Cholangiocarcinoma

Intervention / Treatment
-----------------
* Other: No interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patient must sign an informed consent form; Age 18-75 years old, both male and female; ECOG performance status score (PS score) 0-2; Hilar cholangiocarcinoma with resectable tumor lesions; Complete the upper abdomen MRI examination before treatment; Exclusion Criteria: Accompanied with other primary malignant tumors; Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies; Incomplete imaging or medical history data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sun Yat-Sen Memorial Hospital of Sun Yat-sen University<br>The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the validation cohort. | Other: No interventions<br>* As this is a observational study, there are no interventions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lymph node metastasis status | The value of multiparametric MRI-based clinico-radiomics in predicting lymph node metastasis. | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hilar Cholangiocarcinoma, Lymph Node Metastasis, Radiomics, Machine-learning, Prognosis
Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm

Study Overview
=================
Brief Summary
-----------------
This clinical study evaluates the efficacy and safety of Neuronox compared with Botox in adults with essential blepharospasm.

Detailed Description
-----------------
Subjects are randomly assigned into the two groups at the ratio of 1:1. The purpose of study is to confirm the non-inferiority of Neuronox to Botox in terms of the efficacy and safety in subjects with essential blepharospasm.

Official Title
-----------------
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Essential Blepharospasm

Conditions
-----------------
Essential Blepharospasm

Intervention / Treatment
-----------------
* Drug: Neuronox
* Drug: Botox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults aged 18 to 75 Subjects had to have a confirmed clinical diagnosis of essential blepharospasm requiring treatment by injection Exclusion Criteria: Subjects who underwent surgical operation Subjects with Neuroleptic induced blepharospasm

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Neuronox<br>Botulinum Toxin Type A for injection | Drug: Neuronox<br>* Clostridium Botulinum Toxin A 100 U<br>* Other names: Botulinum Toxin Type A for injection;|
| Active Comparator: Botox<br>Botulinum Toxin Type A for injection | Drug: Botox<br>* Clostridium Botulinum Toxin A 100 U<br>* Other names: Botulinum Toxin Type A for injection;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| JRS (Jankovic Rating Scale) sum-score | Change from baseline at 4 week for the JRS (Jankovic Rating Scale) sum-score | From baseline at 4 week |